On April 26, 2022, the webinar will provide an overview of the regulatory environment for medicines in China, including regulatory authorization pathways. The webinar will be hosted by The Organisation for Professionals in Regulatory Affairs (TOPRA).
April 26, 2022 | 9:30 GMT | Drug Registration Pathways in China
Learning objectives
By engagement in this webinar, the delegate will:
Understand approval pathways for drugs approval in China
Be able to explain key milestones, timelines and dossier requirements for China drug approvals
Target Audience
Regulatory professionals in UK and EU who want to familiarise themselves with the Chinese Regulatory environment for medicines
Investors who want to understand more about key requirements for portfolio companies
Presenters
Guo Ning
General Manager Cisema Beijing
Guo Ning is an industry executive with degrees from Nankai University Tianjin (China) and University of Mannheim (Germany) who has developed a deep expertise in China market access issues via his experiences in industry, as a project manager at an import/export business, and as a technical compliance and product safety expert with Cisema for over 15 years.
Hamish King
COO of Cisema Group
Admitted as a lawyer in Hong Kong and in New South Wales, Australia and formerly with Magic Circle firm Linklaters in Hong Kong, Hamish lives in Hong Kong regularly writes and presents on China regulatory affairs life sciences topics.
Contact Cisema if you would like to learn more about the event or register here.
